A Phase II Study of BAY 43-9006 for Imatinib- and Sunitinib-Resistant Malignant Gastrointestinal Stromal Tumor
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 May 2018
At a glance
- Drugs Sorafenib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 22 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 May 2008 Results to be presented at the Annual Meeting of the American Society of Clinical Oncology 2008.